125 related articles for article (PubMed ID: 34564803)
41. Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.
Kowalski P; Farley KM; Lage H; Schneider E
Anticancer Res; 2004; 24(4):2231-5. PubMed ID: 15330166
[TBL] [Abstract][Full Text] [Related]
42. [Expression of ABCG2 and p-glycoprotein in residual breast cancer tissue after chemotherapy and their correlation with epithelial-mesenchymal transition].
Qu H; Fang L; Duan L; Long X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):236-40. PubMed ID: 24915813
[TBL] [Abstract][Full Text] [Related]
43. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
44. Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines.
Taheri T; Jamialahmadi K; Khadijeh F
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3413-3418. PubMed ID: 29286612
[TBL] [Abstract][Full Text] [Related]
45. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
[TBL] [Abstract][Full Text] [Related]
46. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
[TBL] [Abstract][Full Text] [Related]
47. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
[TBL] [Abstract][Full Text] [Related]
48. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
Kowalski P; Surowiak P; Lage H
Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
[TBL] [Abstract][Full Text] [Related]
49. Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.
Seidel A; Hasmann M; Löser R; Bunge A; Schaefer B; Herzig I; Steidtmann K; Dietel M
Virchows Arch; 1995; 426(3):249-56. PubMed ID: 7773504
[TBL] [Abstract][Full Text] [Related]
50. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
51. Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.
Yang CH; Chen YC; Kuo ML
Anticancer Res; 2003; 23(3B):2519-23. PubMed ID: 12894535
[TBL] [Abstract][Full Text] [Related]
52. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
[TBL] [Abstract][Full Text] [Related]
53. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
54. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
55. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
[TBL] [Abstract][Full Text] [Related]
56. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.
To KK; Tomlinson B
Br J Pharmacol; 2013 Nov; 170(5):1137-51. PubMed ID: 24032744
[TBL] [Abstract][Full Text] [Related]
57. The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines.
Asschert J; de Vries E; van der Kolk D; Müller M; Vellenga E
Leukemia; 1997 May; 11(5):680-6. PubMed ID: 9180292
[TBL] [Abstract][Full Text] [Related]
58. Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
Sinha BK; Perera L; Cannon RE
Biomed Pharmacother; 2019 Dec; 120():109468. PubMed ID: 31605952
[TBL] [Abstract][Full Text] [Related]
59. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
60. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport.
Zhang S; Yang X; Morris ME
Pharm Res; 2004 Jul; 21(7):1263-73. PubMed ID: 15290869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
